We noted you are experiencing viewing problems
- 
        
        Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
- 
        
        Check the following talk links to see which ones work correctly:
 Auto Mode
 HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems.
- 
        
        No luck yet? More tips for troubleshooting viewing issues
- 
        
        Contact HST Support access@hstalks.com
- 
        Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
- 
        For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
                    
                    This is a limited length demo talk; you may
                    
                      login or
                    
                    review methods of
                    obtaining more access.
                  
                
                
              - Scope of the Problem
- 
                                
                                1. Current thinking in back pain management - introduction- Ms. Anna Hlavsova MSc, MCSP, HPC
 
- 
                                
                                2. Genetic epidemiology of low back pain and intervertebral disc degeneration- Dr. Frances Williams
 
- Biomechanics, Spinal Surgery and Research Methods
- 
                                
                                3. The biomechanics of back pain: what we know so far- Prof. Michael Adams
 
- 
                                
                                4. Low back pain: a composite of interacting systems?- Prof. Alison McGregor
 
- 
                                
                                5. What does physiotherapy teach us about back pain?- Ms. Josephine O'Callaghan
 
- 
                                
                                6. How we currently measure back pain- Prof. Rob Froud
 
- 
                                
                                7. Back pain: are we measuring the right things?- Prof. Rob Froud
 
- Chronic Pain and Current Challenges
- 
                                
                                8. The psychosocial flags framework: overcoming obstacles to work- Prof. Kim Burton
 
- Current Therapies and Treatments
- 
                                
                                9. Psychological treatment for people with musculoskeletal pain 1- Prof. Tamar Pincus
 
- 
                                
                                10. Psychological treatment for people with musculoskeletal pain 2- Prof. Tamar Pincus
 
- 
                                
                                11. Current thinking in pain medicine and some thoughts on back pain- Dr. Nick Hacking
 
- 
                                
                                12. Combined physical and psychological programmes plus alternative therapies for back pain- Ms. Anna Hlavsova MSc, MCSP, HPC
 
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- A brief history of LBP measurement
- The original ‘core sets’
- Numerical rating scale and visual analogue scale
- The Roland-Morris disability questionnaire
- Oswestry low back disability questionnaire
- Bombardier updates
- World Health Organisation recommendations
- Most commonly used outcome measures
- Most commonly measured domains in LBP trials
- Are we measuring the right things?
- Properties of instruments
- Reproducibility and responsiveness
- What a measurement instrument should do
- Terwee definition
- What is important?
- Jaeschke’s definition
- ROC curves
- Decision-making from measurements
- Individual-level importance consensus
- Improving outcome interpretation
- Between-group differences
- Group/population importance
- Between-group differences - summary
- Acknowledgement
Topics Covered
- History of low back pain measurement and ‘core sets’
- Properties of measurement instruments
- Using back pain measurements to make decisions
Talk Citation
Froud, R. (2015, November 30). How we currently measure back pain [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 31, 2025, from https://doi.org/10.69645/CFAI1621.Export Citation (RIS)
Publication History
- Published on November 30, 2015
Financial Disclosures
- Prof. Rob Froud has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
      
      
        
                  0:00
                
                
                  
                    Hi, I'm Rob Froud,
                  
                    and welcome to
"How We Currently Measure Back Pain,"
                  
                    which is a talk in the series
                  
                    "Current Thinking
in Back Pain Management."
                  
                    I originally trained
as a manual therapist,
                  
                    and went on to read epidemiology
and medical statistics.
                  
                    I split my time
                  
                    between the Norwegian School
of Health Sciences, in Oslo,
                  
                    and Warwick Medical School,
in the UK.
                  
                
              
                  0:25
                
                
                  
                    So this is just an overview
of the topics
                  
                    I'm going to cover in this talk.
                  
                    I'm gonna first talk about
                  
                    the history of low
back pain measurements
                  
                    and so called 'Core Sets'
of outcome measurements.
                  
                    And then I'm gonna talk about
                  
                    the properties
of these instruments,
                  
                    what makes a good
measurement instrument,
                  
                    what makes a bad one,
and what we expect them to do.
                  
                    And finally,
I'm going to talk about
                  
                    how we use these
instruments to help us
                  
                    manage patients and
populations with back pain.
                  
                    Now this talk focuses on how
we currently measure back pain,
                  
                    but in understanding
our approach to that,
                  
                    there may be a question
rearing its head about
                  
                    whether we're actually
measuring things
                  
                    that are important to patients.
                  
                    And I'll be covering that
in a subsequent talk.
                  
                    And so I'm hoping if I hold
your interest in this talk,
                  
                    you might go on to have
a look at that one too.
                  
                
              
                  1:16
                
                
                  
                    So we've already heard
in the series about
                  
                    how expensive back pain is.
                  
                    In 1998, it was estimated that
                  
                    back pain cost the UK economy
12.3 billion pounds.
                  
                    Somewhere around
a tenth to a third of us
                  
                    have back pain right now,
                  
                    and pretty much all of us
can expect to get it
                  
                    at some point in our life.
                  
                    The lifetime prevalence
is as high as 84 percent.
                  
                    About four percent
of the UK population
                  
                    takes time off work
due to back pain.
                  
                    And this equates to
90 million days lost each year,
                  
                    and 8-12 million GP
consults every year.
                  
                    So I think it's probably
gonna be helpful
                  
                    if I try to sharpen the focus
                  
                    of the scope of
this talk a little bit.
                  
                    It's going to be about
trials, specifically,
                  
                    outcome measures
used in trials.
                  
                    Outcome measure use
in basic science, for example,
                  
                    might be a little bit different
                  
                    to what we're
interested in trials.
                  
                    And secondarily, it's going
to be about pragmatic trials.
                  
                    Now these focus on the benefit
the treatment produces
                  
                    in routine clinical practice
as opposed to efficacy trials
                  
                    which look at the benefit
that's produced
                  
                    under ideal conditions.
                  
                    Now this is pretty easy
to do in drug trials,
                  
                    if you imagine
you have two drugs
                  
                    that are identical,
to same color, same shape,
                  
                    and perhaps even the same taste,
                  
                    it's then easy to blind
everybody in the trial,
                  
                    patients, doctors,
to which is the active pill.
                  
                    And then providing that
the trial was done well,
                  
                    the difference is attributable
to the active ingredients.
                  
                    Now this is much harder to do
                  
                    in trials
of complex interventions
                  
                    like surgery,
manual therapy, or CBT,
                  
                    where what's given
to the patient
                  
                    may consist of many different
but inseparable components.
                  
                    And it's also difficult
to blind people
                  
                    to what they're receiving,
                  
                    so most trials in back pain
are pragmatic in nature.
                  
                    I think it's fair to say
that pragmatic trials are also
                  
                    the most useful
to informing policy,
                  
                    and managing patients
in real-life situations.
                  
                    Now a lot of money is being
spent on back pain trials
                  
                    to get these data.
                  
                    At today's prices, a full scale
randomized control trial costs
                  
                    the thick end
of 2 million pounds.
                  
                    So it was so much
money being spent,
                  
                    it's important that we ensure
                  
                    we are measuring
the right things.
                  
                    So if we start off in the 1970s,
                  
                    the focus at this time
in outcome measurement
                  
                    is really on range
of motion and mobility.
                  
                    And there was a notion
that if you could move again,
                  
                    it meant be all well again,
                  
                    regardless of
whether it still hurts.
                  
                    But in the 1980s, the focus
started to shift towards
                  
                    patient-reported outcome
measures, so called PROMs.
                  
                    And these PROMs
measure latent domains,
                  
                    as well as things that
are readily observable.
                  
                    So by latent domain, I mean,
the domain of health
                  
                    that you and I would
probably agree existed,
                  
                    but that we couldn't go out
and directly measure.
                  
                    So something like
depression, for example,
                  
                    where we couldn't see it
to readily measure it,
                  
                    but we might be able
to devise questions.
                  
                    So these would be
questions about depression,
                  
                    so we could ask about low mood
                  
                    and in order to ensure
we capture the full scale,
                  
                    we might ask about
suicidal ideation.
                  
                    So it might seem odd
to use questionnaires
                  
                    to measure back pain
but essentially,
                  
                    we can't see back pain either.
                  
                    X-ray images and
MRI images of someone
                  
                    with quite crippling back pain
                  
                    can sometimes look a lot
like those of someone
                  
                    without any pain.
                  
                    Conversely, images taken
from someone with no pain
                  
                    can show disc narrowing
and bony growths,
                  
                    the sort of things
that you might
                  
                    reasonably expect
to be associated with back pain.
                  
                    In practice, the way
doctors diagnose back pain
                  
                    is essentially just
by asking the patient
                  
                    whether they have it.
                  
                    Hence this move
towards questionnaires
                  
                    to measure and monitor back pain,
which is essentially sensible
                  
                    so long as we're measuring
the right things.
                  
                    So the '80s and the '90s
saw many PROMs being developed,
                  
                    and it got to the point
where there were
                  
                    so many, and so many trials
                  
                    that used different
outcome measures
                  
                    that made it very difficult
                  
                    to compare outcomes
between trials.
                  
                    And it was difficult
for clinicians as well
                  
                    who might not have
much familiarity
                  
                    with one particular scale,
                  
                    because they were
so many of them.
                  
                    So efforts were made towards
the turn of the millennium
                  
                    to standardize
the outcome measures
                  
                    that were used in trials,
                  
                    and recommends so called
'core sets' of outcome measurements.
                  
                
               
       
    











 
                    
                     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
     
        
      
    